Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC

NCT00276276 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00276276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2000
Completion date
Not reported
Enrollment
141
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, small cell